Publikationsserver
Initiation of Antiresorptive Drug Treatment during Endocrine Therapy for Breast Cancer—A Retrospective Cohort Study of 161,492 Patients in Germany
Endocrine therapy (ET), which significantly reduces breast cancer (BC) recurrence and mortality rates, is the primary systemic therapy for hormone receptor positive BC. However, in addition to frequently reported TAM- and AI-related side effects, such as hot flashes, arthralgias, and myalgias, treat...
I tiakina i:
| Ngā kaituhi matua: | , , , , , |
|---|---|
| Hōputu: | Tuhinga |
| Reo: | Ingarihi |
| I whakaputaina: |
Philipps-Universität Marburg
2023
|
| Ngā marau: | |
| Urunga tuihono: | Kuputuhi katoa PDF |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Whakarāpopototanga: | Endocrine therapy (ET), which significantly reduces breast cancer (BC) recurrence and mortality rates, is the primary systemic therapy for hormone receptor positive BC. However, in addition to frequently reported TAM- and AI-related side effects, such as hot flashes, arthralgias, and myalgias, treatment with AIs in particular leads to accelerated bone loss (AI-associated bone loss, AIBL) and increased bone fracture risk. To the best of our knowledge, little is known about the prescription spectrum of antiresorptive drugs in BC patients treated with ET in Germany. To explore this further, we conducted a retrospective cohort study that included 161,492 patients under ET to measure the cumulative incidence of antiresorptive drug prescription for TAM and AIs and estimate the relationship between initial drug (AIs versus TAM) and antiresorptive drug prescription. Finally, our study provides an overview of the most frequently prescribed antiresorptive drugs in Germany. |
|---|---|
| Whakaahutanga tūemi: | Gefördert durch den Open-Access-Publikationsfonds der UB Marburg. |
| DOI: | 10.3390/cancers15061847 |